An FDA panel voted to let pharmacies compound BPC-157 and TB-500. That is not the same as legal.

On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, epitalon and semax. It declined a seventh, emideltide, which is sold in this market as DSIP.

Every one of those votes was close, and the margins are worth printing rather than summarising. BPC-157, KPV and TB-500 each carried 8 to 6. MOTS-c carried 7 to 5, semax 8 to 5, epitalon 7 to 4. Emideltide failed 6 to 7. A recommendation that turns on one or two members of a fourteen-seat panel is a different object from a consensus, and reporting that says only that the panel 'backed' these compounds loses the thing a reader most needs to know.

The route to that meeting started on 27 February 2026, when the Secretary of Health and Human Services said on a podcast that most of the nineteen peptides then sitting in the FDA's Category 2 would be considered for reclassification. In April twelve were removed from Category 2, after the nominations that put them there were withdrawn. Removal from Category 2 is not placement in Category 1; it only makes a substance eligible to be considered, which is what the July meeting was.

It is worth being exact about what the committee was deciding, because almost every headline got this wrong. The 503A bulks list names substances a licensed compounding pharmacy may use to prepare a medicine for an identified patient who has a prescription for it. Being on that list is not FDA approval. It is not a finding that a compound works. It is not permission to sell anything to anyone, and it says nothing about the material sold as a research chemical.

Nor is the vote the last step. The committee's recommendations do not bind the FDA, which can accept them, reject them, or leave them sitting. Actually adding a substance to the list requires notice-and-comment rulemaking, and the lawyers following the docket put the earliest realistic date in 2027, with a multi-year process entirely possible. Between now and then nothing has changed in law.

Our own index supplies the part of this story that the regulatory coverage leaves out: nobody was waiting. As of 15 September 2026 we hold confirmed listings for BPC-157 from 58 of the vendors we read, MOTS-c from 56, epitalon from 50, KPV from 49, semax from 45 and TB-500 from 39. These are among the most widely sold compounds in the market. A committee spent two days deciding whether pharmacists should be allowed to compound six substances that several dozen websites will already post to your house.

Two things this does not touch. A research-labelled vial is not a compounded prescription and never becomes one, so the route this vote might eventually open runs through a prescriber and a licensed pharmacy rather than through a checkout. And the World Anti-Doping Agency's prohibited list is a separate instrument that no FDA committee votes on; an athlete's position is unchanged.

The regulatory line on each of these six profiles carries the date we last checked it, and those dates now read September 2026. When the FDA opens a rulemaking docket, that is a fact with a date and we will post it here.